Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV002264755 | SCV002546376 | likely benign | Hereditary thrombocytopenia and hematologic cancer predisposition syndrome | 2022-07-08 | reviewed by expert panel | curation | NM_001754.5(RUNX1):c.552G>A (p.Pro184=) is a synonymous variant. REVEL is not calculable for this synonymous variant. SpliceAI predicts: Acceptor loss 0.00, donor loss 0.00, acceptor gain 0.00, donor gain 0.00(BP4). Evolutionary conservation prediction algorithms predict the site as not being conserved (PhyloP score -7.011 < 2.0 or the variant is the reference nucleotide in one primate and/or three mammal species) (BP7).In summary, this variant meets the criteria to be classified as likely benign. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: BP4, BP7. |
Labcorp Genetics |
RCV000945662 | SCV001091702 | likely benign | Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 | 2024-05-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004962964 | SCV005495329 | likely benign | Inborn genetic diseases | 2024-10-05 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |